Evaluación de la respuesta de anticuerpos neutralizantes a la vacuna Sputnik V en una cohorte en Córdoba y evaluación de las propiedades neutralizantes de anticuerpos naturales y vacunales frente a la variante Manaos

Se evaluó la respuesta de anticuerpos tipo IgG totales anti S y anticuerpos neutralizantes (AcNT) a la vacuna Sputnik V en 800 muestras tomadas a una cohorte de 285 personas en la ciudad de Córdoba. Las muestras fueron tomadas en tres momentos diferentes: una muestra basal previo a lo colocación de la vacuna (en los casos en que fue posible), una muestra luego de la primera dosis de la vacuna (día 14) y una muestra luego de la segunda dosis correspondiente (día 42 desde la 1er dosis). El promedio de la edad de las personas que conforman la cohorte es de 39,24 (±9,76), con un mínimo de 20 años y un máximo de 65 años. El 26,67% de ellos (n=76) tuvieron exposición previa al virus SARS-CoV-2. La determinación de anticuerpos tipo IgG contra la proteína S del virus se realizó mediante las técnicas COVIDAR IgG (Laboratorio Lemos S.R.L.) y SARS-CoV-2 IgG II Quant (Abbott). Las muestras que resultaron discordantes o negativas se evaluaron por inmunofluorescencia indirecta “in house” (IFI). La capacidad neutralizante de los 2 anticuerpos en las muestras de las personas vacunadas se evaluó por una técnica de Neutralización por reducción de placas (TNRP) frente al virus salvaje SARS-CoV-2 (hCoV19/Argentina/PAIS-G0001/2020, GISAID ID: EPI_ISL_499083) utilizando células Vero Cl76 (ATCC CRL-587). Los anticuerpos neutralizantes fueron titulados, estableciéndose como el título a la máxima dilución del plasma con capacidad de neutralizar al menos el 80% de las Unidades Formadoras de Placa (UFP) inoculadas, como previamente ha sido descripto (Blanco y col., 2021).Fil: Rodríguez, Rodolfo. Gobierno de Córdoba. Instituto Provincial de Investigación y Planificación Sanitaria; Argentina.Fil: Caeiro, Juan Pablo. Universidad Nacional de Córdoba; Argentina.Fil: Caeiro, Juan Pablo. Universidad Católica de Córdoba. Facultad de Medicina; Argentina.Fil: Juri, Hugo. Universidad Nacional de Córdoba. Rectorado; Argentina.Fil: Juri, Hugo. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Juri, Hugo. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Pizzi, Rogelio. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Gallego, Sandra. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Blanco, Sebastián. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Konigheim, Brenda. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Spinsanti, Lorena. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Díaz, Adrian. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Aguilar, Juan. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Beranek, Mauricio. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Rivarola, María Elisa. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Nates, Silvia. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Ré, Viviana. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Pisano, Belén. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología “Dr. J.M. Vanella”; Argentina.Fil: Mangeaud, Arnaldo. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales; Argentina.Fil: Díaz, Miguel. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Collino, César. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Barrera, Aldo Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Álvarez, Alejandra. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Ravera, Lorena. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Zappia, Liliana. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Brarda, Canela. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Eynard Asua, Josefina. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Toledo, Claudia. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Barrientos Alvarado, Carla Daniela. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina.Fil: Sabbatini, Julia. Gobierno de Córdoba. Ministerio de Salud. Hospital Rawson; Argentina

The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data

The FLUXNET2015 dataset provides ecosystem-scale data on CO2, water, and energy exchange between the biosphere and the atmosphere, and other meteorological and biological measurements, from 212 sites around the globe (over 1500 site-years, up to and including year 2014). These sites, independently managed and operated, voluntarily contributed their data to create global datasets. Data were quality controlled and processed using uniform methods, to improve consistency and intercomparability across sites. The dataset is already being used in a number of applications, including ecophysiology studies, remote sensing studies, and development of ecosystem and Earth system models. FLUXNET2015 includes derived-data products, such as gap-filled time series, ecosystem respiration and photosynthetic uptake estimates, estimation of uncertainties, and metadata about the measurements, presented for the first time in this paper. In addition, 206 of these sites are for the first time distributed under a Creative Commons (CC-BY 4.0) license. This paper details this enhanced dataset and the processing methods, now made available as open-source codes, making the dataset more accessible, transparent, and reproducible.Peer reviewe

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Anthracene as a sensitiser for near-infrared luminescence in complexes of Nd(III) Er(III) and Yb(III) : an unexpected sensitisation mechanism based on electron transfer

The ligand L1, which contains a chelating 2-(2-pyridyl)benzimidazole (PB) unit with a pendant anthacenyl group An connected via a methylene spacer, (L1 = PB-An), was used to prepare the 8-coordinate lanthanide(III) complexes [Ln(hfac)3(L1)] (Ln = Nd, Gd, Er, Yb) which have been structurally characterised and all have a square antiprismatic N2O6 coordination geometry. Whereas free L1 displays typical anthracene-based fluorescence, this fluorescence is completely quenched in its complexes. The An group in L1 acts as an antenna unit: in the complexes [Ln(hfac)3(L1)] (Ln = Nd, Er, Yb) selective excitation of the anthracene results in sensitised near-infrared luminescence from the lanthanide centres with concomitant quenching of An fluorescence. Surprisingly, the anthracene fluorescence is also quenched even in the Gd(III) complex and in its Zn(II) adduct in which quenching via energy transfer to the metal centre is not possible. It is proposed that the quenching of anthracene fluorescence in coordinated L1 arises due to intra-ligand photoinduced electron-transfer from the excited anthracene chromophore 1An* to the coordinated PB unit generating a short-lived charge-separated state [An˙+–PB˙−] which collapses by back electron-transfer to give 3An*. This electron-transfer step is only possible upon coordination of L1 to the metal centre, which strongly increases the electron acceptor capability of the PB unit, such that 1An* → PB PET is endoergonic in free L1 but exergonic in its complexes. Thus, rather than a conventional set of steps (1An* → 3An* → Ln), the sensitization mechanism now includes 1An* → PB photoinduced electron transfer to generate charge-separated [An˙+–PB˙−], then back electron-transfer to generate 3An* which finally sensitises the Ln(III) centre via energy transfer. The presence of 3An* in L1 and its complexes is confirmed by nanosecond transient absorption studies, which have also shown that the 3An* lifetime in the Nd(III) complex matches the rise time of Nd-centred near-infrared emission, confirming that the final step of the sequence is 3An* → Ln(III) energy-transfer

Reprints and permissions:

sagepub.co.uk/journalsPermissions.na

Effect of Intraoperative High Positive End-Expiratory Pressure (PEEP) With Recruitment Maneuvers vs Low PEEP on Postoperative Pulmonary Complications in Obese Patients: A Randomized Clinical Trial (vol 321, pg 2292, 2019)

status: publishe